Last updated: May 25, 2026
ABACAVIR SULFATE + LAMIVUDINE Suppliers: Who Manufactures the API and Fixed-Dose Combo Inputs?
Reliable supply of abacavir sulfate and lamivudine depends on (1) API manufacturers for each active ingredient and (2) formulation and packaging suppliers for the fixed-dose combination tablets (and, where applicable, downstream dosage strengths). Supplier selection typically hinges on FDA DMF coverage for APIs, quality system capability (US/ICH), ability to support ANDA/BLA-ready documentation, and audit/qualification status in the finished-dose channel.
The market for abacavir sulfate and lamivudine is mature, with longstanding API sources and multiple finished-dose originators and generic suppliers. Fixed-dose abacavir/lamivudine tablets are typically produced by generic and contract manufacturers using sourced APIs that are already qualified via Drug Master Files (DMFs) and supplier qualification packages.
Which companies supply abacavir sulfate and lamivudine APIs for pharma manufacturing?
Featured snippet answer: API supply is typically provided by global specialty API manufacturers with FDA DMFs and a track record in antiretroviral manufacturing. For abacavir sulfate and lamivudine, common supplier archetypes include Indian and Chinese API producers with DMF portfolios and Western/JP-linked specialty chemical suppliers supplying through contract channels to branded and generic finished-dose manufacturers.
Common API supplier categories (practical procurement view)
- API manufacturers with active US DMFs: sell abacavir sulfate or lamivudine (often as nucleoside analogues) directly to finished-dose manufacturers and packagers.
- Specialty chemical intermediates suppliers: support the API supply chain via key intermediates, typically under long-term supply agreements.
- CMOs for finished-dose tablets: source APIs from qualified suppliers and handle tableting, coating, packaging, and batch release.
Abacavir sulfate API supply: what to look for in a supplier
- DMF status in the US: whether the API is covered by an active Drug Master File referenced by ANDA sponsors.
- Regulatory and quality readiness: cGMP compliance, controlled impurity profiles, and viral safety controls where applicable to nucleoside analog workflows.
- Particle size and form control: abacavir sulfate polymorph and PSD control affect tableting and dissolution.
Lamivudine API supply: what to look for in a supplier
- Crystal form and impurity controls: lamivudine’s impurity specifications and residual solvents carry through to finished-dose dissolution and stability.
- Scalability and audit outcomes: stable supply during generic launches and seasonal demand shifts.
What are the main finished-dose and combo-drug supply routes for abacavir/lamivudine tablets?
Featured snippet answer: Finished-dose supply routes usually fall into three lanes: (1) brand originators, (2) US generic manufacturers with ANDA approvals, and (3) CMOs that produce tablets on contract using qualified APIs.
Fixed-dose combination context
- Abacavir sulfate/lamivudine tablets are typically supplied as generic or branded products, with API sourced from qualified manufacturers.
- Finished-dose tablet supply depends on:
- supplier qualification for both APIs,
- validated granulation and tableting methods,
- packaging line availability (bottles, cartons, blister packs),
- batch release controls.
CMO vs. direct manufacturer procurement
- Many finished-dose companies outsource to CMOs for tableting and packaging.
- CMOs often require that the client’s API supplier set is pre-qualified or that the CMO will qualify new API sources via internal audits.
Which generic manufacturers commonly source abacavir sulfate and lamivudine APIs?
Featured snippet answer: Generic manufacturers typically source APIs from established DMF holders and qualified API manufacturers. The finished-dose market includes multiple ANDA-approved sponsors, and each sponsor’s drug product supply chain uses specific API DMF references.
Procurement reality
- In practice, the finished-dose sponsor’s ANDA filing history is the fastest way to identify likely API sources, because the API DMF referenced in the ANDA ties directly to the API supplier.
- Contract manufacturers also tend to use a limited set of qualified API suppliers to control risk during regulatory review cycles.
How do FDA DMF references determine who the real suppliers are?
Featured snippet answer: The most defensible way to identify the API supplier is to map the finished-dose ANDA or listed drug to the referenced FDA DMF for each API.
Why DMF mapping is central
- ANDA formulations cite the API DMF number(s) and cross-reference controlled documents.
- DMF holders are effectively the authorized API suppliers for the commercial dossier referenced in approvals.
What procurement teams do
- Request the DMF cross-reference package from the sponsor or through the API sales team.
- Verify the specific DMF holder, site address, and right-to-evoke documentation.
What patent estate affects abacavir sulfate and lamivudine supplier commercialization?
Featured snippet answer: The APIs for abacavir and lamivudine are mature products. For fixed-dose combinations, the patent estate that matters is typically limited to specific formulation, method-of-use, and combination-related exclusivities that can constrain certain generic or modified-release submissions.
Key commercial effect
- If formulation patents or manufacturing method patents exist for a specific strength or tablet design, suppliers may still provide the API, but finished-dose entry can be constrained by product-level IP.
Supplier impact
- API suppliers are often insulated if they sell the API generally, while finished-dose manufacturers face regulatory and IP barriers tied to drug product submissions.
When does exclusivity end for abacavir/lamivudine products and what does it mean for supplier switching?
Featured snippet answer: For mature antiretroviral tablets, most composition-of-matter and marketing exclusivities have expired, making supply switching largely an operational and qualification-driven exercise rather than an exclusivity-driven one.
Operational effect
- Post-expiration periods primarily affect:
- ANDA entry timelines,
- commercial ramp-up for finished-dose tablets,
- demand spikes for APIs.
What generic entry risks exist for abacavir sulfate and lamivudine fixed-dose tablets?
Featured snippet answer: Entry risks are mainly dossier and quality risks rather than API availability. The dominant constraints are bioequivalence package readiness, manufacturing controls, and IP clean status for the specific drug product.
Risk categories
- Bioequivalence and dissolution reproducibility
- Impurity and residual solvent compliance
- IP “product-by-product” constraints (method of manufacture, formulation)
Which formulation and manufacturing factors can constrain API supplier interchangeability?
Featured snippet answer: Even when APIs meet pharmacopeial specifications, differences in impurity profiles, PSD, crystal form, and moisture content can affect finished-dose dissolution and stability. That can restrict “drop-in” supplier substitution without revalidation.
Key compatibility checkpoints
- In-process controls: blend uniformity, granulation end-point, tablet hardness.
- Stability: moisture uptake and degradation kinetics.
- Dissolution: early-release differences from PSD and particle morphology.
Key Takeaways
- API supply for abacavir sulfate and lamivudine is mature; practical supplier identification hinges on FDA DMF references tied to ANDA drug product approvals.
- Finished-dose supply is constrained mainly by product-level dossier readiness and formulation/manufacturing reproducibility rather than by core API scarcity.
- Supplier interchangeability is limited by particle attributes, impurity profiles, and downstream dissolution and stability performance.
FAQs
1) How can procurement teams identify the actual API suppliers for abacavir sulfate and lamivudine?
Map each finished-dose ANDA sponsor to the referenced FDA DMF for each API, then verify DMF holder and manufacturing site.
2) Do abacavir sulfate and lamivudine have multiple DMFs from different holders?
Typically yes in mature APIs, and ANDA sponsors may reference different DMF holders over time. The authoritative mapping is the DMF reference within the approved submission.
3) What criteria matter most when qualifying a new lamivudine API supplier?
Impurity profile consistency, crystal form control, residual solvent levels, PSD, and stability performance in the finished formulation.
4) Can a finished-dose manufacturer switch abacavir sulfate API suppliers without new bioequivalence work?
Often no. Changes that affect dissolution, impurities, or tablet process outcomes can require supplemental comparability and, in some cases, additional regulatory work.
5) What supply-chain bottlenecks most often affect abacavir/lamivudine tablet availability?
Finished-dose manufacturing capacity, packaging line constraints, and qualification delays for replacement APIs or changed suppliers.
References
- FDA. “Drug Master Files (DMFs).” U.S. Food and Drug Administration (official guidance and information pages).
- FDA. “ANDA Submissions: Chemistry, Manufacturing, and Controls (CMC) Information.” U.S. Food and Drug Administration (official guidance pages).
- FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. FDA (database).
